Article in Japanese

Surveilance result for the oseltamivir dose and use of 3 mg/kg for patients less than 1 year of age with Influenza in Japan

Yoshitake SATO¹⁾, Masayoshi SHINJOH¹⁾, Masaaki MORI¹⁾, Kazunobu OUCHI²⁾, Hiroyuki TSUSUMI³⁾

Influenza is a respiratory infection caused by influenza virus. Infants are at especially high risk of developing severe encephalopathy. In Japan, medical doctors want to use medicine for internal use. In 2012, the Food and Drug Administration (FDA) approved oseltamivir for treatment of influenza in infants less than 1 year of age. Accordingly, in 2012, at the "Evaluation committee on unapproved or off-label-use drugs with high medical needs"of MHLW (Ministry of Health, Labour and Welfare), the Japanese Society for Pediatric Infectious Diseases (JSPID) and two other societies requested the development of oseltamivir for infants. In 2015-2016, members of JSPID conducted a dose and use survey of oseltamivir 3 mg/kg in infants. As a result, 22 patients were dosed with oseltamivir 3 mg/kg (1 patient was administered for prophylactic use). Eighteen of the 21 patients were administered 3 mg/kg bid of oseltamivir for 5 days. It was judged to be effective in 18 patients. In this survey, no adverse events were reported such as vomiting and diarrhea as observed in EU and US. In summary, we think that oseltamivir is useful for the treatment of influenza in infants.

---

1) members of the pharmaceutical affairs committee, Japanese Society for Pediatric Infectious Diseases
2) President, Japanese Society for Pediatric Infectious Diseases
3) former President, Japanese Society for Pediatric Infectious Diseases

Key words
Received	January 1, 1970
Accepted	January 1, 1970

29 (1)：83─88,2017